

Erika Vacchelli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1441930/erika-vacchelli-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

9,062
citations

51
h-index

88
g-index

88
ext. papers

10,622
ext. citations

9.2
avg, IF

5.5
L-index

#	Paper	IF	Citations
85	Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. <i>Science</i> , 2011 , 334, 1573-7	33.3	939
84	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014 , 20, 1301-9	50.5	596
83	Consensus guidelines for the detection of immunogenic cell death. <i>Oncotarget</i> , 2014 , 5, 12472-508	7.2	524
82	Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. <i>Immunity</i> , 2013 , 38, 729-41	32.3	439
81	Regulation of autophagy by cytosolic acetyl-coenzyme A. <i>Molecular Cell</i> , 2014 , 53, 710-25	17.6	331
80	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
79	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016 , 30, 147-160	24.3	285
78	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015 , 350, 972-8	33.3	267
77	Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. <i>Science Translational Medicine</i> , 2012 , 4, 143ra99	17.5	266
76	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015 , 6, 588	8.4	239
75	Mitochondrial gateways to cancer. <i>Molecular Aspects of Medicine</i> , 2010 , 31, 1-20	16.7	210
74	Regulation of autophagy by stress-responsive transcription factors. <i>Seminars in Cancer Biology</i> , 2013 , 23, 310-22	12.7	187
73	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. <i>Oncotarget</i> , 2012 , 3, 1323-1343	7.2	173
72	Trial watch: IDO inhibitors in cancer therapy. <i>Oncotarget</i> , 2014 , 5, 12472-508	7.2	166
71	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. <i>Oncotarget</i> , 2012 , 3, 1323-1343	7.2	164
70	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncotarget</i> , 2012 , 3, 1323-1343	7.2	163
69	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncotarget</i> , 2015 , 6, 10088-66	7.2	162

68	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolmunology</i> , 2012 , 1, 1111-1134	7.2	134
67	Trial Watch: Toll-like receptor agonists for cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e25238	7.2	120
66	Trial Watch: Chemotherapy with immunogenic cell death inducers. <i>Oncolmunology</i> , 2014 , 3, e27878	7.2	116
65	Crosstalk between ER stress and immunogenic cell death. <i>Cytokine and Growth Factor Reviews</i> , 2013 , 24, 311-8	17.9	106
64	Prognostic impact of vitamin B6 metabolism in lung cancer. <i>Cell Reports</i> , 2012 , 2, 257-69	10.6	100
63	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. <i>Oncolmunology</i> , 2016 , 5, e1149673	7.2	99
62	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019 , 10, 1486	17.4	95
61	Trial watch: Oncolytic viruses for cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e24612	7.2	94
60	Trial watch: Cardiac glycosides and cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e23082	7.2	89
59	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e25771	7.2	87
58	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , 2014 , 3, e27297	7.2	86
57	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Oncolmunology</i> , 2012 , 1, 179-188	7.2	86
56	Trial Watch: Peptide vaccines in cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e26621	7.2	84
55	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. <i>Oncolmunology</i> , 2014 , 3, e28473	7.2	83
54	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , 2012 , 1, 28-37	7.2	80
53	Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. <i>Oncogene</i> , 2013 , 32, 4995-5004	9.2	80
52	Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. <i>Cell Cycle</i> , 2012 , 11, 3851-60	4.7	79
51	Trial watch: Monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e22789	7.2	76

50	Trial Watch: Anticancer radioimmunotherapy. <i>Oncolmunology</i> , 2013 , 2, e25595	7.2	75
49	Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. <i>Autophagy</i> , 2012 , 8, 413-5	10.2	74
48	Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. <i>Oncolmunology</i> , 2012 , 1, 1640-1642	7.2	73
47	Trial watch: Peptide vaccines in cancer therapy. <i>Oncolmunology</i> , 2012 , 1, 1557-1576	7.2	73
46	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Oncolmunology</i> , 2013 , 2, e23510	7.2	72
45	Trial watch: DNA vaccines for cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e23803	7.2	70
44	Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. <i>Cell Death and Differentiation</i> , 2014 , 21, 59-68	12.7	66
43	Trial Watch: Immunostimulatory cytokines. <i>Oncolmunology</i> , 2012 , 1, 493-506	7.2	66
42	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , 2014 , 3, e27048	7.2	64
41	Trial Watch: Toll-like receptor agonists in oncological indications. <i>Oncolmunology</i> , 2014 , 3, e29179	7.2	61
40	ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. <i>Oncolmunology</i> , 2013 , 2, e24568	7.2	61
39	Trial watch: STING agonists in cancer therapy. <i>Oncolmunology</i> , 2020 , 9, 1777624	7.2	61
38	Trial Watch: Adoptive cell transfer immunotherapy. <i>Oncolmunology</i> , 2012 , 1, 306-315	7.2	58
37	TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. <i>Oncolmunology</i> , 2018 , 7, e1462431	7.2	55
36	Organs on chip approach: a tool to evaluate cancer-immune cells interactions. <i>Scientific Reports</i> , 2017 , 7, 12737	4.9	54
35	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmunology</i> , 2016 , 5, e1214790	7.2	51
34	Trial watch: Immunostimulatory cytokines in cancer therapy. <i>Oncolmunology</i> , 2014 , 3, e29030	7.2	47
33	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmunology</i> , 2020 , 9, 1777625	7.2	45

32	Autophagy induction for the treatment of cancer. <i>Autophagy</i> , 2016 , 12, 1962-1964	10.2	44
31	Trial Watch: Immunostimulatory cytokines. <i>Oncolmunology</i> , 2013 , 2, e24850	7.2	44
30	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>Oncolmunology</i> , 2013 , 2, e24238	7.2	43
29	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. <i>Cancer Research</i> , 2016 , 76, 3122-6	10.1	42
28	Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. <i>Oncotarget</i> , 2015 , 6, 20840-50	3.3	41
27	The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma. <i>Oncolmunology</i> , 2016 , 5, e1218106	7.2	39
26	Trial Watch: Lenalidomide-based immunochemotherapy. <i>Oncolmunology</i> , 2013 , 2, e26494	7.2	39
25	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolmunology</i> , 2019 , 8, e1657375	7.2	38
24	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmunology</i> , 2015 , 4, e985940	7.2	38
23	Cell death signaling and anticancer therapy. <i>Frontiers in Oncology</i> , 2011 , 1, 5	5.3	36
22	Trial Watch-Immunostimulation with cytokines in cancer therapy. <i>Oncolmunology</i> , 2016 , 5, e1115942	7.2	35
21	Coffee induces autophagy in vivo. <i>Cell Cycle</i> , 2014 , 13, 1987-94	4.7	34
20	Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. <i>Oncolmunology</i> , 2012 , 1, 271-278	7.2	33
19	Independent transcriptional reprogramming and apoptosis induction by cisplatin. <i>Cell Cycle</i> , 2012 , 11, 3472-80	4.7	31
18	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>Oncolmunology</i> , 2014 , 3, e28344	7.2	30
17	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. <i>Oncolmunology</i> , 2020 , 9, 1796002	7.2	25
16	Current trends of anticancer immunochemotherapy. <i>Oncolmunology</i> , 2013 , 2, e25396	7.2	24
15	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. <i>Cell Cycle</i> , 2013 , 12, 417-214.7		24

14	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolmmunology</i> , 2020 , 9, 1771143	7.2	23
13	Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo. <i>Cell Cycle</i> , 2015 , 14, 2399-407	4.7	22
12	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. <i>Oncolmmunology</i> , 2015 , 4, e988042	7.2	21
11	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Oncolmmunology</i> , 2016 , 5, e1139275	7.2	17
10	Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. <i>Oncolmmunology</i> , 2016 , 5, e1118600	7.2	14
9	Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. <i>Oncolmmunology</i> , 2019 , 8, e1498285	7.2	14
8	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021 , 11, 408-423	24.4	12
7	Chemical activation of SAT1 corrects diet-induced metabolic syndrome. <i>Cell Death and Differentiation</i> , 2020 , 27, 2904-2920	12.7	11
6	Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. <i>Oncolmmunology</i> , 2016 , 5, e1064581	7.2	11
5	Contribution of annexin A1 to anticancer immunosurveillance. <i>Oncolmmunology</i> , 2019 , 8, e1647760	7.2	10
4	Fluorescent biosensors for the detection of HMGB1 release. <i>Methods in Molecular Biology</i> , 2013 , 1004, 43-56	1.4	10
3	Autophagy-mediated metabolic effects of aspirin. <i>Cell Death Discovery</i> , 2020 , 6, 129	6.9	8
2	No impact of cancer and plague-relevant polymorphisms on COVID-19. <i>Oncolmmunology</i> , 2020 , 9, 1857112	7.2	2
1	A loss-of-function polymorphism in compromises therapeutic outcome in head and neck carcinoma patients.. <i>Oncolmmunology</i> , 2022 , 11, 2059878	7.2	0